Dr. Christopher Rohde is the co-founder and Chief Technology Officer of Factor Bioscience, which he joined in early 2012 following the completion of his Ph.D. at the Massachusetts Institute to Technology. Dr. Rohde is also the co-founder of Novellus Therapeutics, where he served as President until its acquisition by Brooklyn in 2021. Chris has extensive experience developing mRNA technologies and technologies for high-throughput and high-content screening and is the named inventor on more than 100 patents. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many others.